CR Turner, CJ Andresen, WB Smith and JW Watson
Department of Immunology and Infectious Diseases, Pfizer Central Research, Groton, CT 06340.

The following study was performed to test the hypothesis that treatment with rolipram, a specific inhibitor of phosphodiesterase (PDE) IV, should inhibit many pulmonary responses to acute and chronic antigen challenge in atopic monkeys by elevating intracellular cAMP and subsequently inhibiting leukocyte function. Monkeys received subcutaneous injections of either vehicle (2% DMSO) or 10 mg/kg of rolipram 1 h before exposure to Ascaris suum antigen (Ag). Acute responses to Ag, including bronchoconstriction, pulmonary leukocyte infiltration, and cytokine production, were monitored before and 4 h after single Ag aerosol administration. To monitor the effects of rolipram on chronic Ag exposure, a 10-d, multiple-Ag protocol, previously demonstrated to induce airway hyperresponsiveness (AHR) to methacholine (MCh), was performed. Ag exposure increased respiratory system resistance (Rrs) 221.7 +/- 31.88% (n = 5). This increase in Rrs was not significantly altered by rolipram. Rolipram significantly (p < 0.002) increased cAMP levels in bronchoalveolar lavage (BAL) leukocytes 1 h after administration (n = 5). Ag-induced increases in BAL IL-8 and TNF were significantly reduced by rolipram, but IL-1 beta and IL-6 increases were unaffected (n = 9). Ag-induced increases in BAL eosinophils and neutrophils were significantly reduced by rolipram (n = 9). In the multiple-Ag protocol (n = 7), rolipram significantly reduced both the number of BAL eosinophils (p < 0.02) and the development of AHR (p < 0.002). Despite its inability to inhibit acute Ag-induced bronchoconstriction, rolipram was protective against acute and chronic inflammatory responses to Ag and prevented the development of AHR, suggesting that selective PDE-IV inhibition is a relevant target for asthma therapy.

This article has been cited by other articles:

				T. Bopp, N. Dehzad, S. Reuter, M. Klein, N. Ullrich, M. Stassen, H. Schild, R. Buhl, E. Schmitt, and C. Taube Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated Suppression J. Immunol., April 1, 2009; 182(7): 4017 - 4024. [Abstract] [Full Text] [PDF]

				M. Mellado, A. M. de Ana, L. Gomez, C. Martinez-A, and J. M. Rodriguez-Frade Chemokine Receptor 2 Blockade Prevents Asthma in a Cynomolgus Monkey Model J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 769 - 775. [Abstract] [Full Text] [PDF]

				M. R. Van Scott, J. L. Hooker, D. Ehrmann, Y. Shibata, C. Kukoly, K. Salleng, G. Westergaard, A. Sandrasagra, and J. Nyce Dust mite-induced asthma in cynomolgus monkeys J Appl Physiol, April 1, 2004; 96(4): 1433 - 1444. [Abstract] [Full Text] [PDF]

				L. Zhang, M. P. Soares, Y. Guan, S. Matheravidathu, R. Wnek, K. E. Johnson, A. Meisher, S. A. Iliff, J. S. Mudgett, M. S. Springer, et al. Functional Expression and Characterization of Macaque C-C Chemokine Receptor 3 (CCR3) and Generation of Potent Antagonistic Anti-macaque CCR3 Monoclonal Antibodies J. Biol. Chem., September 6, 2002; 277(37): 33799 - 33810. [Abstract] [Full Text] [PDF]

				N. Hayashida, S. Chihara, E. Tayama, T. Takaseya, N. Enomoto, T. Kawara, and S. Aoyagi Antiinflammatory effects of colforsin daropate hydrochloride, a novel water-soluble forskolin derivative Ann. Thorac. Surg., June 1, 2001; 71(6): 1931 - 1938. [Abstract] [Full Text] [PDF]

				A. KANEHIRO, T. IKEMURA, M. J. MÄKELÄ, M. LAHN, A. JOETHAM, A. DAKHAMA, and E. W. GELFAND Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen Challenge Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 173 - 184. [Abstract] [Full Text]

				T. Ikemura, J. Schwarze, M. Makela, A. Kanehiro, A. Joetham, K. Ohmori, and E. W. Gelfand Type 4 Phosphodiesterase Inhibitors Attenuate Respiratory Syncytial Virus-Induced Airway Hyper-Responsiveness and Lung Eosinophilia J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 701 - 706. [Abstract] [Full Text]

				G. Hartmann, C. Bidlingmaier, B. Siegmund, S. Albrich, J. Schulze, K. Tschoep, A. Eigler, H. A. Lehr, and S. Endres Specific Type IV Phosphodiesterase Inhibitor Rolipram Mitigates Experimental Colitis in Mice J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 22 - 30. [Abstract] [Full Text]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				D. C. Underwood, S. Bochnowicz, R. R. Osborn, C. J. Kotzer, M. A. Luttmann, D. W.P. Hay, P. D. Gorycki, S. B. Christensen, and T. J. Torphy Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 988 - 995. [Abstract] [Full Text]

				J. B. Madwed and A. C. Jackson Determination of airway and tissue resistances after antigen and methacholine in nonhuman primates J Appl Physiol, November 1, 1997; 83(5): 1690 - 1696. [Abstract] [Full Text] [PDF]

				R. B. Dowling, M. Johnson, P. J. Cole, and R. Wilson The Effect of Rolipram, a Type IV Phosphodiesterase Inhibitor, on Pseudomonas aeruginosa Infection of Respiratory Mucosa J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1565 - 1571. [Abstract] [Full Text]

				T. J. TORPHY Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370. [Full Text]